Cargando…
Phosphodiesterase inhibitors /
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of thes...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego :
Academic Press,
1996.
|
| Colección: | Handbook of immunopharmacology. Drugs.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn162129160 | ||
| 003 | OCoLC | ||
| 005 | 20231117014752.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 070802s1996 cauaf ob 001 0 eng d | ||
| 040 | |a OPELS |b eng |e pn |c OPELS |d OCLCQ |d OCLCE |d N$T |d YDXCP |d IDEBK |d E7B |d MERUC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d OCLCA |d STF |d D6H |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d LEAUB |d INARC |d LUN |d S2H |d OCLCO |d OCLCQ |d OCLCO |d COM |d OCLCO |d OCLCQ | ||
| 019 | |a 182545914 |a 605593064 |a 647688907 |a 649983730 |a 823830173 |a 823899873 |a 824091146 |a 824139023 |a 974745901 |a 974865048 |a 987673474 |a 989464277 |a 1035659241 |a 1086559853 | ||
| 020 | |a 9780122107207 | ||
| 020 | |a 0122107209 | ||
| 020 | |a 9780080538815 |q (electronic bk.) | ||
| 020 | |a 0080538819 |q (electronic bk.) | ||
| 020 | |a 1281058971 | ||
| 020 | |a 9781281058973 | ||
| 035 | |a (OCoLC)162129160 |z (OCoLC)182545914 |z (OCoLC)605593064 |z (OCoLC)647688907 |z (OCoLC)649983730 |z (OCoLC)823830173 |z (OCoLC)823899873 |z (OCoLC)824091146 |z (OCoLC)824139023 |z (OCoLC)974745901 |z (OCoLC)974865048 |z (OCoLC)987673474 |z (OCoLC)989464277 |z (OCoLC)1035659241 |z (OCoLC)1086559853 | ||
| 042 | |a dlr | ||
| 050 | 4 | |a QP609.P53 |b P578 1996eb | |
| 060 | 4 | |a QU 143 P575 1996 | |
| 072 | 7 | |a MED |x 008000 |2 bisacsh | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a MMG |2 bicssc | |
| 082 | 0 | 4 | |a 612.01513 |2 22 |
| 084 | |a VS 9200 |2 rvk | ||
| 084 | |a WD 5065 |2 rvk | ||
| 084 | |a WD 5090 |2 rvk | ||
| 084 | |a XI 6600 |2 rvk | ||
| 245 | 0 | 0 | |a Phosphodiesterase inhibitors / |c edited by Christian Schudt, Gordon Dent and Klaus F. Rabe. |
| 260 | |a San Diego : |b Academic Press, |c 1996. | ||
| 300 | |a 1 online resource (xvi, 228 pages, 2 unnumbered pages of plates) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a The Handbook of immunopharmacology. Drugs | |
| 520 | |a Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting. Key Features * Utilizes actual testing and research of new PDE inhibitors * Valuable for researchers and students alike. | ||
| 505 | 0 | |a K.M. Ferguson and K. Loughney, Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods. -- H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods. -- K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function. -- R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions. -- R. Fischmeister, EHNA as an Inhibitor of PDE II. -- V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents. -- M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential. -- P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors. -- J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I. -- A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors. -- R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344. -- J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401. -- T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV. -- Subject Index. | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods -- Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods -- Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes nad cellular function -- Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase (PDEI) -- EHNA as an inhibitor of PDE2; a pharmacological and biochemical study in cardiac myocytes -- cGMP-inhibited phosphodiesterases (PDE3) -- Interaction of PDE4 inhibitors with enzymes and cell functions -- Inhibition of phosphodiesterase isoenzymes and cell function by selective PDE5 inhibitors -- Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5 -- Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors -- An isoform-selective inhibitor of cyclic AMP-specific phosphodiesterase (PDE4) with anti-inflammatory properties -- Characterization of different states of PDE4 by rolipram and RP 73041 -- Molecular aspects of inhibitor interaction with PDE4. | |
| 506 | |3 Use copy |f Restrictions unspecified |2 star |5 MiAaHDL | ||
| 533 | |a Electronic reproduction. |b [Place of publication not identified] : |c HathiTrust Digital Library, |d 2010. |5 MiAaHDL | ||
| 538 | |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. |u http://purl.oclc.org/DLF/benchrepro0212 |5 MiAaHDL | ||
| 583 | 1 | |a digitized |c 2010 |h HathiTrust Digital Library |l committed to preserve |2 pda |5 MiAaHDL | |
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a Phosphodiesterases |x Inhibitors. | |
| 650 | 0 | |a Phosphodiesterases |x Inhibitors |x Therapeutic use. | |
| 650 | 2 | |a Phosphodiesterase Inhibitors |x therapeutic use |0 (DNLM)D010726Q000627 | |
| 650 | 2 | |a Phosphodiesterase Inhibitors |x pharmacology |0 (DNLM)D010726Q000494 | |
| 650 | 6 | |a Phosphodiest�erases |0 (CaQQLa)201-0082615 |x Inhibiteurs. |0 (CaQQLa)201-0380642 | |
| 650 | 6 | |a Phosphodiest�erases |0 (CaQQLa)201-0082615 |x Inhibiteurs |0 (CaQQLa)201-0380642 |x Emploi en th�erapeutique. |0 (CaQQLa)201-0373975 | |
| 650 | 7 | |a MEDICAL |x Biochemistry. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Aufsatzsammlung |2 gnd |0 (DE-588)4143413-4 | |
| 650 | 7 | |a Immunpharmakologie |2 gnd |0 (DE-588)4026639-4 | |
| 650 | 7 | |a Inhibitor |2 gnd |0 (DE-588)4027007-5 | |
| 650 | 7 | |a Phosphodiesterasen |2 gnd |0 (DE-588)4174389-1 | |
| 700 | 1 | |a Schudt, Christian. | |
| 700 | 1 | |a Dent, Gordon. | |
| 700 | 1 | |a Rabe, Klaus F. | |
| 776 | 0 | 8 | |i Print version: |t Phosphodiesterase inhibitors. |d San Diego : Academic Press, 1996 |z 0122107209 |z 9780122107207 |w (OCoLC)35682108 |
| 830 | 0 | |a Handbook of immunopharmacology. |p Drugs. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780122107207 |z Texto completo |